10:44 AM
 | 
Jul 11, 2018
 |  BC Extra  |  Company News

Shanghai Junshi licenses anti-PD-1 mAb to CSPC

Shanghai Junshi Biosciences Co. Ltd. (Shanghai, China) granted CSPC Pharmaceutical Group Ltd. (HKSE:1093) exclusive rights in China, including Hong Kong and Macau, and Taiwan to develop and commercialize an undisclosed anti-PD-1 mAb in combination with albumin-bound paclitaxel to treat breast cancer.

Junshi is eligible for RMB150 million ($22.7 million) in milestones, comprising five separate milestones valued at RMB30 million ($4.5 million).

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

Purchase this article for limited one-time distribution and website posting

$750 USD